GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

3rd August 2026

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Subject: Media release: Q1 of 2026-27

Please find enclosed a press release issued by the Company in respect to financial results for the quarter ended 30th June 2026.

This is for your information and record.

Yours faithfully
For **GlaxoSmithKline Pharmaceuticals Limited**

AJAY AVINASH NADKARNI

Digitally signed by AJAY AVINASH NADKARNI
Date: 2026.08.03 16:05:53 +05'30'

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151

GSK

PRESS RELEASE

GSK India Delivers Strong Q1FY27 Growth With Continued Portfolio Transformation, Profit After Tax (PAT) grows 24% to INR 253 Crores

3rd August 2026

Mumbai: GlaxoSmithKline Pharmaceuticals Ltd (GSK India) today announced its financial results for the first quarter ended 30th June 2026. During the quarter, the Company delivered strong growth across both its core and innovative portfolios. The performance reflects continued progress in the Company's portfolio transformation strategy, supplemented by execution excellence, and a favourable base effect from the comparable period last year.

Revenue for the quarter stood at INR 924 crores, up 15% Y-o-Y. Profit After Tax (PAT) increased by 24% to INR 253 crores, while EBITDA margins stood at 32%.

The General Medicines portfolio grew strongly during the quarter, with the top five promoted brands outperforming the market (EI* >100; Source: IQVIA). Key promoted brands such as *Augmentin*, *Ceftum* and *T-Bact* reinforced their leadership positions in their respective categories, driven by a combination of deeper scientific and in-clinic engagement, omnichannel execution, and pricing measures. The Respiratory portfolio continued to further the management of chronic respiratory diseases with *Nucala (mepolizumab)* benefitting a large number of patients and *Trelegy Ellipta* gaining traction through new access pathways.

The Vaccines business grew through continued leadership in the self-pay private paediatric vaccines market, led by *Infanrix Hexa* and *Fluarix Tetra*. In the adult vaccination space, the Company's focus on elderly patient-cohorts with underlying Cardiovascular and Metabolic Diseases (CVMD) led to stronger endorsement from the healthcare professional community, translating to higher vaccinations with *Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted).*

The Oncology business, led by specialised therapies *Jemperli (dostarlimab)* and *Zejula (niraparib),* has grown significantly since its launch in August last year. *Jemperli* is now the leading immunotherapy for first line primary advanced and recurrent endometrial cancer while *Zejula* is among the top PARP** inhibitors in the maintenance treatment of recurrent ovarian cancer (Source: IPSOS MAT December 2025). Together, both therapies have touched the lives of a growing number of women suffering from gynecological malignancies, with GSK committed to expanding access and patient reach.

Commenting on the results, **Mr. Bhushan Akshikar, Managing Director, GSK India**, said: "GSK India's broad-based growth demonstrates the resilience of the core General Medicines and Vaccines portfolio and the growing contribution of the innovative business. This growth was enabled by a relentless focus on scientific excellence, sharper execution in the field and meaningful investments in technology and talent development. With a strong innovation pipeline and launch opportunities ahead, we are well-positioned to deliver sustainable growth and meaningful impact for millions of patients in India."

*The **Evolution Index** (EI) is a metric used to evaluate the performance of a product relative to the overall market growth. EI>100 means the product is growing faster than the market.
** PARP: Poly (ADP-ribose) polymerase
*** BCMA: B-cell maturation antigen, ADC: Antibody-drug-conjugates

The Company has made progress in strengthening supply chain resilience through diversified sourcing, enhanced contingency planning and improved end-to-end visibility, substantially mitigating disruptions experienced in recent quarters.

Looking ahead, GSK India is preparing for key pipeline launches. *Blenrep (belantamab mafodotin)*, an anti-BCMA ADC*** therapy indicated for second-line treatment in relapsed or refractory multiple myeloma in adults, is set for launch. *Arexvy*, a vaccine to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults over 60 years of age and older adults (50 to 59 years) at high-risk, has received marketing authorisation.

About GSK India

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology and talent to get ahead of disease together.
For more information, visit www.gsk-india.com.

Media Contacts
Communications and Government Affairs
Carson Dalton – carson.a.dalton@gsk.com
Farah Bookwala – farah.a.bookwala@gsk.com

*The **Evolution Index** (EI) is a metric used to evaluate the performance of a product relative to the overall market growth. EI>100 means the product is growing faster than the market.
** PARP: Poly (ADP-ribose) polymerase
*** BCMA: B-cell maturation antigen, ADC: Antibody-drug-conjugates